Journal Article

Clinical use of TIMP-2•IGFBP7 biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panel

Engelman, Daniel T., Joannidis, Michael, Binnall, Brian, Zarbock, Alexander, Bergler, Tobias, Ronco, Claudio, Guzzi, Louis M., Gluck, Eric, Kellum, John A., Reddy, V. Seenu, Rimmelé, Thomas, Koyner, Jay L., Forni, Lui, Göcze, Ivan, Germain, Michael J., Textoris, Julien

2019

Overview

Background The first FDA-approved test to assess risk for acute kidney injury (AKI), [TIMP-2]•[IGFBP7], is clinically available in many parts of the world, including the USA and Europe. We sought to understand how the test is currently being used clinically. Methods We invited a group of experts knowledgeable on the utility of this test for kidney injury to a panel discussion regarding the appropriate use of the test. Specifically, we wanted to identify which patients would be appropriate for testing, how the results are interpreted, and what actions would be taken based on the results of the test. We used a modified Delphi method to prioritize specific populations for testing and actions based on biomarker test results. No attempt was made to evaluate the evidence in support of various actions however. Results Our results indicate that clinical experts have developed similar practice patterns for use of the [TIMP-2]•[IGFBP7] test in Europe and North America. Patients undergoing major surgery (both cardiac and non-cardiac), those who were hemodynamically unstable, or those with sepsis appear to be priority patient populations for testing kidney stress. It was agreed that, in patients who tested positive, management of potentially nephrotoxic drugs and fluids would be a priority. Patients who tested negative may be candidates for “fast-track” protocols. Conclusion In the experience of our expert panel, biomarker testing has been a priority after major surgery, hemodynamic instability, or sepsis. Our panel members reported that a positive test prompts management of nephrotoxic drugs as well as fluids, while patients with negative results are considered to be excellent candidates for “fast-track” protocols.

• Publisher: BioMed Central,BioMed Central Ltd,BMC
• Subject: Acute kidney failure / Acute kidney injury / Acute Kidney Injury - classification / Acute Kidney Injury - diagnosis / Binding proteins / Biological markers / Biomarker testing / Biomarkers - analysis / Biomarkers - blood / Clinical guidelines / Critical care / Critical Care Medicine / Emergency Medicine / Enzyme inhibitors / Expert panel / Humans / Insulin / Insulin-Like Growth Factor Binding Proteins - analysis / Insulin-Like Growth Factor Binding Proteins - blood / Intensive / Measurement / Medical tests / Medicine / Medicine & Public Health / Methods / Physiological aspects / Protein binding / Protocols / Risk factors / Technology / Tissue Inhibitor of Metalloproteinase-2 - analysis / Tissue Inhibitor of Metalloproteinase-2 - blood